<DOC>
	<DOCNO>NCT01372007</DOCNO>
	<brief_summary>Total mesorectal excision ( TME ) precise dissection rectum para-rectal lymph node within mesorectal envelope . It become universally recognize accepted standard technique surgical excision rectum carcinoma . TME result low rate local recurrence , especially combine pre-operative chemo-radiotherapy . Especially pre-operative chemo-radiotherapy , post-operative drainage may important . The quick decrease drainage enable early mobilisation patient may shorten time hospitalization . If decrease fluid production achieve , positive effect Quality Life patient ensure health economic saving reduction hospitalization time resource . Somatostatin analogues show able decrease secretion numerous type bodily fluid . The aim study investigate lanreotide Autogel 120mg capable reduce fluid discharge patient underwent TME rectumcarcinoma . Lanreotide Autogel 120mg compare placebo , administer post-surgery fluid discharge drain patient underwent total mesorectum excision ( TME ) rectal carcinoma . Patient plan TME ask participate study . When provide write informed consent , randomize 1:1 receive either placebo lanreotide autogel 120mg . Drain fluid check hematocrit daily post-surgery . Once hematocrit level drain fluid &lt; 10 % , study medication placebo administer . After administration volume drain fluid measure every 12 hour least 5 day . A sample drain fluid collect every 24 hour least 5 day frozen -70Â°C total protein content , sodium chloride analysis afterwards . If patient hematocrit &gt; 10 % drain fluid period 5 day , patient randomize .</brief_summary>
	<brief_title>Influence Somatuline Autogel 120mg Post-operative Drainage After Total Mesorectum Excision Rectumcarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>male female patient 1875 year write informed consent participate study schedule total mesorectal excision ( TME ) rectumcarcinoma patient know intolerance somatostatin analogue , lanreotide 's excipients patient young 18 year patient unable provide write informed consent patient receive somatostatin 's analogue last 30 day start study Pregnant breastfeed woman Women use contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rectal carcinoma</keyword>
</DOC>